Aktuelle Entwicklungen und Perspektiven zielgerichteter Therapien

Current Developments and Perspectives in Targeted Therapies Many
different approaches for improving the prognosis of patients with
advanced non-small-cell lung cancer (NSCLC) are currently being
investigated. This article discusses the significance of
maintenance therapy after primary chemotherapy and reviews study
data on second-generation epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs), inhibitors of insulin-like growth
factor receptors (IGFR), vascular-disrupting agents (VDAs) and
multi-TKIs of vascular endothelial growth factor receptors (VEGFR).
The article also looks at the future prospects of using genetic
markers in the field of NSCLC.